A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
A phase 1/2 trial of Serplulimab in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Henlius Biotech, now recruiting.
Overview
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06848699 by Shanghai Henlius Biotech, with 105 participants planned, started 2025-02-25 and due to reach its primary completion in 2026-10-30. Interventions recorded: HLX43 dose 1, HLX43 dose 2, HLX43 dose 3, HLX43 dose 4, HLX43 dose 5. Conditions listed: Solid Tumor Cancer, Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
Shares Serplulimab, Shanghai Henlius Biotech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
Shares Serplulimab, Shanghai Henlius Biotech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage
Shares Serplulimab, Shanghai Henlius Biotech, Small-cell lung cancer.
- TrialTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Shares Serplulimab, Shanghai Henlius Biotech, Small-cell lung cancer.
- TrialA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Shares Serplulimab, Shanghai Henlius Biotech.
- TrialA Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
Shares Serplulimab, Shanghai Henlius Biotech, Non-small-cell lung cancer.
- TrialA Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
- TrialA Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta
Shares Serplulimab, Shanghai Henlius Biotech.